

Agreement 3: Rheumatoid Arthritis Functional Improvement Contract

Parties: BioRheumatix GmbH and German National Insurance Fund Country: Germany Disease Area:

Moderate to Severe Rheumatoid Arthritis Agreement Overview: This agreement represents a sophisticated approach to managing biologic therapy costs while optimizing patient outcomes in rheumatoid arthritis. Built on the principles of the German healthcare system's emphasis on functional improvement, this contract covers approximately 1,850 patients with moderate to severe RA who have failed conventional DMARDs. The agreement incorporates multiple validated clinical assessment tools and emphasizes returning patients to normal activities of daily living and workforce participation.

Financial Structure:

- Initial payment: €3,800 per 3-month treatment cycle (standard care pathway)
- Outcomes-based rebates:
 - 30% rebate (€1,140) if <50% of patients achieve ACR20 response by week 12
 - 20% rebate (€760) if <40% of patients show improved HAQ-DI scores of at least 0.22 points
 - Population-level assessment conducted by independent rheumatology registry
- Bonus structure: Additional €1,200 per patient achieving remission (DAS28 <2.6) maintained for 6+ months
- Risk corridor: Manufacturer absorbs costs exceeding €45,000 per patient per year (includes medication, administration, and monitoring)
- Patient co-pay reduction: From 20% to 5% when clinical targets met, encouraging adherence
- Workforce participation incentive: €2,500 bonus payment for each incremental 5% of patients maintaining employment above baseline

Duration: 2 years with option to extend based on predefined performance criteria Special Provisions:

- Includes comprehensive rehabilitation services package (physical therapy, occupational therapy)
- Productivity measurement tools and workplace accommodation consultation
- Specialized nursing support through dedicated RA care coordinators
- Digital symptom tracking platform with alert system for disease flares
- Standardized ultrasound imaging protocol for joint damage assessment
- Patient registry participation with anonymous data sharing for research
- Annual multidisciplinary case conferences for complex patients